14.84
-0.01(-0.07%)
Currency In USD
| Previous Close | 14.85 |
| Open | 14.86 |
| Day High | 15 |
| Day Low | 14.6 |
| 52-Week High | 17.15 |
| 52-Week Low | 3.72 |
| Volume | 4.71M |
| Average Volume | 1.79M |
| Market Cap | 2.07B |
| PE | -7.13 |
| EPS | -2.08 |
| Moving Average 50 Days | 13.58 |
| Moving Average 200 Days | 9.04 |
| Change | -0.01 |
If you invested $1000 in Cogent Biosciences, Inc. (COGT) since IPO date, it would be worth $333.93 as of October 23, 2025 at a share price of $14.84. Whereas If you bought $1000 worth of Cogent Biosciences, Inc. (COGT) shares 5 years ago, it would be worth $1,329.75 as of October 23, 2025 at a share price of $14.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
GlobeNewswire Inc.
Oct 20, 2025 12:32 PM GMT
Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this yearNDA submission for bezuclastinib planned by YE
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 29, 2025 8:05 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on September 25,
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
GlobeNewswire Inc.
Aug 26, 2025 12:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a